Yuekang Pharmaceutical: Super long-acting innovative antihypertensive drug YKYY029 injection II clinical trial initiated.

According to Yuexiang Pharmaceutical, on April 10, the kick-off meeting for the Phase II clinical project of YKYY029 injection developed by its subsidiary Beijing Yuexiang Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd. was held at Third Hospital of Peking University. Following the meeting, the project team will immediately start the patient selection process for the Phase II clinical trial, accelerating the development progress of this innovative siRNA long-acting antihypertensive drug. This drug breaks through the traditional mechanism of antihypertensive drugs, targeting and silencing AGT mRNA through the interference mechanism of siRNA at the source, effectively blocking the synthesis of AGT protein. It is expected to achieve a "one injection every six months" long-lasting antihypertensive effect. Compared with existing drugs, it has the advantages of fewer side effects and longer administration time.